---
figid: PMC4539069__ECAM2015-975632.001
figlink: /pmc/articles/PMC4539069/figure/fig1/
number: Figure 1
caption: 'Proposed model for the complex cross talk between various receptors and
  mediators in early phase response in allergic rhinitis. 1: nerve growth factor (NGF)
  activates tyrosine kinase A (TrkA) receptor which in turn increases production and
  release of substance P (SP). Activation of TrkA receptor also initiates signalling
  via the PI3K/PIP3 pathway to increase expression and sensitivity of transient receptor
  potential vallinoid (TRPV1) receptor. 2: chemokine receptors (CCR2, CCR3, and CXCR8)
  sensitize TRPV1 receptor via a PLCβ/PKC pathway. 3: TRPV1 receptor increases production
  and release of proinflammatory neuropeptides SP and CGRP which act synergistically
  to promote degranulation of primed mast cells. Histamine released by mast cells
  activates histamine 1 receptor (H1R) producing signalling via the phospholipase
  A2/lipoxygenase pathway to activate TRPV1, triggering early phase allergic inflammatory
  response. 4: chemokine receptors are heterologously desensitized by both adenosine
  (A2a) receptors and opioid receptors (MOR, DOR, and KOR). 5: Substance P is inhibited
  by met-enkephalin via Mu opioid receptors (MOR). A2a: adenosine 2a receptor, CCR2,
  CCR3: CC chemokine receptors 2 & 3, CXCR8: CXC chemokine receptor 8, PLCβ: phospholipase
  C β, PKC: protein kinase C, NGF: nerve growth factor, TRPV1: transient receptor
  potential vallinoid 1, TrkA: tyrosine kinase A receptor, H1R: histamine 1 receptor,
  SP: substance P, CGRP: calcitonin gene-related peptide, PI3K/PIP3: phosphatidylinositol
  3 kinase/phosphatidylinositol phosphate 3 pathway, PLA2/LO: phospholipase A2/lipoxygenase
  pathway, MOR: Mu opioid receptor, DOR: delta opioid receptor, KOR: kappa opioid
  receptor, and MEK: met-enkephalin.'
pmcid: PMC4539069
papertitle: Mediators, Receptors, and Signalling Pathways in the Anti-Inflammatory
  and Antihyperalgesic Effects of Acupuncture.
reftext: John L. McDonald, et al. Evid Based Complement Alternat Med. 2015;2015:975632.
pmc_ranked_result_index: '32719'
pathway_score: 0.9388725
filename: ECAM2015-975632.001.jpg
figtitle: Proposed model for the complex cross talk between various receptors and
  mediators in early phase response in allergic rhinitis
year: '2015'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4539069__ECAM2015-975632.001.html
  '@type': Dataset
  description: 'Proposed model for the complex cross talk between various receptors
    and mediators in early phase response in allergic rhinitis. 1: nerve growth factor
    (NGF) activates tyrosine kinase A (TrkA) receptor which in turn increases production
    and release of substance P (SP). Activation of TrkA receptor also initiates signalling
    via the PI3K/PIP3 pathway to increase expression and sensitivity of transient
    receptor potential vallinoid (TRPV1) receptor. 2: chemokine receptors (CCR2, CCR3,
    and CXCR8) sensitize TRPV1 receptor via a PLCβ/PKC pathway. 3: TRPV1 receptor
    increases production and release of proinflammatory neuropeptides SP and CGRP
    which act synergistically to promote degranulation of primed mast cells. Histamine
    released by mast cells activates histamine 1 receptor (H1R) producing signalling
    via the phospholipase A2/lipoxygenase pathway to activate TRPV1, triggering early
    phase allergic inflammatory response. 4: chemokine receptors are heterologously
    desensitized by both adenosine (A2a) receptors and opioid receptors (MOR, DOR,
    and KOR). 5: Substance P is inhibited by met-enkephalin via Mu opioid receptors
    (MOR). A2a: adenosine 2a receptor, CCR2, CCR3: CC chemokine receptors 2 & 3, CXCR8:
    CXC chemokine receptor 8, PLCβ: phospholipase C β, PKC: protein kinase C, NGF:
    nerve growth factor, TRPV1: transient receptor potential vallinoid 1, TrkA: tyrosine
    kinase A receptor, H1R: histamine 1 receptor, SP: substance P, CGRP: calcitonin
    gene-related peptide, PI3K/PIP3: phosphatidylinositol 3 kinase/phosphatidylinositol
    phosphate 3 pathway, PLA2/LO: phospholipase A2/lipoxygenase pathway, MOR: Mu opioid
    receptor, DOR: delta opioid receptor, KOR: kappa opioid receptor, and MEK: met-enkephalin.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CCR3
  - PRKCB
  - PRKD3
  - TRPV1
  - CCR2
  - PRKCD
  - PRKCA
  - NTRK1
  - TP53INP2
  - PIK3R3
  - MAP2K1
  - PRKCE
  - PRKCG
  - OPRK1
  - PIK3CD
  - PIK3CG
  - S100A12
  - PIK3CB
  - PLCB4
  - PIK3R5
  - MAP2K2
  - PLCB3
  - PIK3R6
  - PRKCZ
  - PIK3R4
  - NGF
  - PRKCQ
  - PLCB2
  - PLCB1
  - PRKCI
  - PIK3CA
  - PRKCH
  - Adenosine
  - Histamine
  - Cancer
genes:
- word: CCR3
  symbol: CCR3
  source: hgnc_symbol
  hgnc_symbol: CCR3
  entrez: '1232'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCB
  entrez: '5579'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKD3
  entrez: '23683'
- word: TRPV1
  symbol: TRPV1
  source: hgnc_symbol
  hgnc_symbol: TRPV1
  entrez: '7442'
- word: CCR2
  symbol: CCR2
  source: hgnc_symbol
  hgnc_symbol: CCR2
  entrez: '729230'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCD
  entrez: '5580'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCA
  entrez: '5578'
- word: trkA
  symbol: TRKA
  source: hgnc_alias_symbol
  hgnc_symbol: NTRK1
  entrez: '4914'
- word: DOR
  symbol: DOR
  source: hgnc_alias_symbol
  hgnc_symbol: TP53INP2
  entrez: '58476'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCE
  entrez: '5581'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCG
  entrez: '5582'
- word: KOR
  symbol: KOR
  source: hgnc_alias_symbol
  hgnc_symbol: OPRK1
  entrez: '4986'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: CGRP
  symbol: CGRP
  source: hgnc_alias_symbol
  hgnc_symbol: S100A12
  entrez: '6283'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PLCB
  symbol: PLCB
  source: bioentities_symbol
  hgnc_symbol: PLCB4
  entrez: '5332'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PLCB
  symbol: PLCB
  source: bioentities_symbol
  hgnc_symbol: PLCB3
  entrez: '5331'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCZ
  entrez: '5590'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: NGF
  symbol: NGF
  source: hgnc_symbol
  hgnc_symbol: NGF
  entrez: '4803'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCQ
  entrez: '5588'
- word: PLCB
  symbol: PLCB
  source: bioentities_symbol
  hgnc_symbol: PLCB2
  entrez: '5330'
- word: PLCB
  symbol: PLCB
  source: bioentities_symbol
  hgnc_symbol: PLCB1
  entrez: '23236'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCI
  entrez: '5584'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCH
  entrez: '5583'
chemicals:
- word: Adenosine
  source: MESH
  identifier: D000241
- word: Histamine
  source: MESH
  identifier: D006632
diseases:
- word: Cancer
  source: ''
  identifier: ''
---
